Filtering by content type: Press Release
As part of the Federal Trade Commission's systematic review of all current FTC rules and guides, the FTC is seeking public comment on the costs, benefits, and regulatory and economic impact of its rule specifying Test Procedures and Labeling Standards for Recycled Oil (“Recycled Oil Rule”).
The Federal Trade Commission issued an administrative complaint challenging the merger of two top suppliers of chloride process titanium dioxide (“TiO2”), a white pigment used in a wide variety of products including paint, industrial coatings, plastic, and paper.
The Federal Trade Commission has proposed amendments to the R-value Rule, which governs ratings for home insulation, as part of its systematic review of all current FTC rules and guides.
The number of reverse-payment patent settlements entered into by pharmaceutical companies in fiscal year 2015 declined from fiscal year 2014, marking a second annual decrease in such settlements, according to a new FTC staff report.
Moonlight Slumber, LLC, an Elgin, Illinois-based firm that advertised its baby mattresses as organic and free of volatile organic compounds (VOCs), has agreed to settle Federal Trade Commission charges that it misrepresented or could not support its claims to consumers. The case is the FTC’s first...
The Federal Trade Commission has closed its investigation of several agreements between Honeywell International, Inc. and E.I. DuPont de Nemours & Co.1 related to the sale of 1234yf, the next generation refrigerant in automotive air conditioning systems.
Following a public comment period, the Federal Trade Commission has approved a final order resolving concerns that the acquisition of the Valspar Corporation by The Sherwin-Williams Company would likely allow the new company to exercise unilateral market power in the North American market for...
In testimony presented to the U.S. House of Representatives’ Judiciary Committee Subcommittee on Regulatory Reform, Commerical and Antitrust Law, the Federal Trade Commission described its efforts to stop anticompetitive conduct in the pharmaceutical industry.
Baxter International Inc. and Claris Lifesciences Limited have agreed to divest two types of pharmaceutical products to settle Federal Trade Commission charges that Baxter’s proposed $625 million acquisition of Claris’ injectable drugs business is anticompetitive.According to a complaint filed by...
Filtering by content type: Case
Baxter International Inc. and Claris Lifesciences Limited have agreed to divest two types of pharmaceutical products to settle charges that Baxter’s proposed $625 million acquisition of Claris’ injectable drugs business would (1) reduce current competition in the United States for the...
Filtering by content type: Public Statement
Filtering by content type: Report
Filtering by content type: Federal Register Notice
Filtering by content type: Closing Letter